Xeris Biopharma Holdings, Inc. (XERS) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

21/25

Growth 5 Margin 5 Expansion 5 Platform 2 Financial 4

latest quarter score

Earnings Reports

21
Xeris Biopharma (XERS) Q2 2026: Recorlev Soars 81%, Secures Durable Growth Platform
August 06, 2026
16
Xeris (XERS) Q1 2026: Recorlev Surges 95%, Fueling Raised Guidance and Pipeline Ambitions
May 07, 2026
22
Xeris (XERS) Q4 2025: Recorlev Patient Base Doubles, Unlocking 44% Revenue Surge
March 02, 2026
21
Xeris (XERS) Q3 2025: Recorlev Patient Growth Surges 108%, Fueling Scalability Push
November 06, 2025
17
Xeris (XERS) Q2 2025: RecorLev Surges 136% as Commercial Portfolio Drives Guidance Hike
August 07, 2025
21
Xeris (XERS) Q1 2025: RecoraLev Revenue Surges 141%, Anchoring 48% Total Growth
July 07, 2025
Xeris Biopharma (XERS) Q4 2024: Recorlev Revenue Surges 131%, Driving 30% Growth Outlook for 2025
March 06, 2025

Browse all companies